Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics surges on cream formulation success

The cream has been formulated to contain SkinBioTherapeutics' proprietary technology, SkinBiotix; tests have proved the cream formulation retains the same beneficial properties as the original technology
Woman applying make-up
SkinBioTherapeutics' technology uses extracts of probiotic bacteria that protect the skin from infection by out-competing harmful pathogens

Skin health specialist SkinBioTherapeutics PLC (LON:SBTX) said the 'cream' formulation of its SkinBiotix technology has passed effectiveness studies in models of skin.

The cream formulation will now undergo further testing for stability in the coming weeks.

WATCH: Industry heavyweights 'sitting up and taking notice' of SkinBio's technology

The company's SkinBiotix platform uses extracts of probiotic bacteria for application to the skin and SkinBio has shown in skin models that its technology can improve the skin's barrier function.

The data from the tests showed a direct correlation between the amount of SkinBiotix within the cream and the level present of a specific protein essential to the barrier function of the skin. Work on creating skin lotion and gel formulations is ongoing.

"The incorporation of our SkinBiotix technology into an effective cream formulation is a major milestone in the development of products for the cosmetic market and, subject to stability testing, allows us to create formulations for our human study later this year," said Dr Catherine O'Neill, the chief executive officer of SkinBioTherapeutics.

Shares in SkinBio opened 6.4% higher at 10.375p.

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use